cp wire

CP Wire Articles

Additional Results from Phase I Study Show Inovio's INO-5150 Stabilizing Effect on Prostate Cancer

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced on 5/18/18 a poster presentation of additional prostate cancer data (Abstract #229675) at the American Society of Clinical Oncology (ASCO)... read more

Fri, 05/18/18 - 09:35 am
Precision Cancer Company Accent Therapeutics Launches with $40 Million Series A Round

Accent Therapeutics, a biopharmaceutical company developing breakthrough treatments for cancer patients, today announced $40 million in Series A capital to establish a discovery platform and... read more

Fri, 05/18/18 - 09:24 am
BeiGene Initiates Phase 3 Trial of Pamiparib as Maintenance Therapy in Patients with Ovarian Cancer

BeiGene, Ltd. (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of... read more

Thu, 05/17/18 - 09:53 am
Intellia Therapeutics Announces WT1 for treating Acute Myeloid Leukemia as Its First Cell Therapy Target

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology, and its research collaborator, Ospedale San... read more

Thu, 05/17/18 - 09:35 am
Exelixis and Ipsen Announce European Approval of Cabometyx for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma

  • Exelixis will receive a milestone payment of $50 million
  • Approval based on Cabometyx vs versus sunitinib in CABOSUN trial
  • Cabometyx was approved for reimbursement in... read more
Thu, 05/17/18 - 09:17 am

Pages